Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | STAT3 | P40763 | 2/20 | 0.49 |
| ▸ | ELANE | P08246 | 8/20 | 0.48 |
| ▸ | CTSG | P08311 | 7/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | RECQL | P46063 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067750 | 0.81 | MAOA (0.56) | MAOAMAPTALDH1A1MAPK1TDP1 | |
| SCHEMBL868062 | 0.81 | MAOA (0.56) | MAOAMAPTALDH1A1MAPK1TDP1 | |
| SCHEMBL868007 | 0.78 | MAOA (0.67) | MAOAMAPTALDH1A1MAPK1TDP1 | |
| SCHEMBL11803308 | 0.75 | MAPT (0.71) | MAOAMAPTALDH1A1MAPK1TDP1 | |
| SCHEMBL10037435 | 0.74 | MAOA (0.56) | MAOAMAPTALDH1A1MAPK1TDP1 | |
| Anthrarufin SCHEMBL187843 | 0.74 | MAOA (1.00) | MAOAMAPTALDH1A1MAPK1TDP1 | |
| Anthrarufin SCHEMBL29363946 | 0.74 | MAOA (1.00) | MAOAMAPTALDH1A1MAPK1TDP1 | |
| Anthrarufin SCHEMBL29874705 | 0.74 | MAOA (1.00) | MAOAMAPTALDH1A1MAPK1TDP1 | |
| Danthron SCHEMBL28137084 | 0.73 | MAPT (0.91) | MAOAMAPTALDH1A1MAPK1TDP1 | |
| Danthron SCHEMBL29356886 | 0.72 | MAPT (1.00) | MAOAMAPTALDH1A1MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2436669-B1 | Preparation of anticancer-active tricyclic compounds via alkyne coupling reaction | TAHEEBO JAPAN CO LTD (JP) | 2016-01-13 | — | — | EP | disclosed |
| EP-2436669-B1 | Preparation of anticancer-active tricyclic compounds via alkyne coupling reaction | TAHEEBO JAPAN CO LTD (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-8703979-B2 | Preparation of anticancer-active tricyclic compounds via alkyne coupling reaction | TAHEEBO JAPAN CO., LTD. (JP) | 2014-04-22 | — | — | US | disclosed |
| US-8703979-B2 | Preparation of anticancer-active tricyclic compounds via alkyne coupling reaction | TAHEEBO JAPAN CO., LTD. (JP) | 2014-04-22 | — | — | US | disclosed |
| US-8703979-B2 | Preparation of anticancer-active tricyclic compounds via alkyne coupling reaction | TAHEEBO JAPAN CO., LTD. (JP) | 2014-04-22 | — | — | US | disclosed |
| US-20120077986-A1 | NOVEL PREPARATION OF ANTICANCER-ACTIVE TRICYCLIC COMPOUNDS VIA ALKYNE COUPLING REACTION | TAHEEBO JAPAN CO., LTD. (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20120077986-A1 | NOVEL PREPARATION OF ANTICANCER-ACTIVE TRICYCLIC COMPOUNDS VIA ALKYNE COUPLING REACTION | TAHEEBO JAPAN CO., LTD. (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20120077986-A1 | NOVEL PREPARATION OF ANTICANCER-ACTIVE TRICYCLIC COMPOUNDS VIA ALKYNE COUPLING REACTION | TAHEEBO JAPAN CO., LTD. (JP) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077986-A1 | NOVEL PREPARATION OF ANTICANCER-ACTIVE TRICYCLIC COMPOUNDS VIA ALKYNE COUPLING REACTION | NR2C2, NR0B2, NR4A2 | MAOA 1290/4885MAPT 4425/4885ALDH1A1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.